Below are the financial statements of Halozyme Therapeutics, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.
| All figures in millions of USD | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenues | — | — | — |
| Royalties | 570.99a | 447.87a | 360.48a |
| Product sales, net | 303.49a | 300.85a | 191.03a |
| Revenues under collaborative agreements | 140.84a | 80.53a | 108.61a |
| Total revenues | 1,015.32a | 829.25a | 660.12a |
| Operating expenses | — | — | — |
| Cost of sales | -159.42a | -192.36a | -139.3a |
| Amortization of intangibles | -71.05a | -73.77a | -43.15a |
| Research and development | -79.05a | -76.36a | -66.61a |
| Selling, general and administrative | -154.34a | -149.18a | -143.53a |
| Total operating expenses | -463.85a | -491.68a | -392.59a |
| Operating income | 551.48a | 337.57a | 267.53a |
| Other income (expense) | — | — | — |
| Investment and other income, net | 23.75a | 16.32a | 1.05a |
| Inducement expense related to convertible notes | 0a | 0a | -2.71a |
| Contingent liability fair value measurement gain | 0a | 13.2a | 0a |
| Interest expense | -18.1a | -18.76a | -16.95a |
| Income before income tax expense | 557.13a | 348.33a | 248.92a |
| Income tax expense | -113.04a | -66.74a | -46.79a |
| Net income | 444.09a | 281.59a | 202.13a |
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Halozyme Therapeutics’s data sources below and access millions more through our Disclosure Search.